The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Open accessAbstract
Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for global economy and health. Vaccination is one of the most effective interventions to substantially reduce severe disease and death due to SARS‐CoV‐2 infection. Vaccination programmes are being rolled out globally, but most of these vaccines have been approved without extensive studies on their side‐effects and efficacy. Recently, new‐onset autoimmune phenomena after COVID‐19 vaccination have been reported increasingly (e.g. immune thrombotic thrombocytopenia, autoimmune liver diseases, Guillain–Barré syndrome, IgA nephropathy, rheumatoid arthritis and systemic lupus erythematosus). Molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants seem to be substantial contributors to autoimmune phenomena. However, whether the association between COVID‐19 vaccine and autoimmune manifestations is coincidental or causal remains to be elucidated. Here, we summarize the emerging evidence about autoimmune manifestations occurring in response to certain COVID‐19 vaccines. Although information pertaining to the risk of autoimmune disease as a consequence of vaccination is controversial, we merely propose our current understanding of autoimmune manifestations associated with COVID‐19 vaccine. In fact, we do not aim to disavow the overwhelming benefits of mass COVID‐19 vaccination in preventing COVID‐19 morbidity and mortality. These reports could help guide clinical assessment and management of autoimmune manifestations after COVID‐19 vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Johnson & Johnson and AstraZeneca), elicit robust humoral responses and have shown safety in the majority of populations vaccinated [12].”
BackgroundThrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
A global database of COVID-19 vaccinations
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01122-8 · Cited by 1,974
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., & Lester, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105385 · Cited by 964
Diagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808
COVID-19 vaccines: modes of immune activation and future challenges
Teijaro, J. R., & Farber, D. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00526-x · Cited by 701
Cited by
Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01086-x · Cited by 450
Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study
Chang, R., Yen-Ting Chen, T., Wang, S.-I., Hung, Y.-M., Chen, H.-Y., & Wei, C.-C. J. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101783 · Cited by 308
Efe, C., Kulkarni, A. V., Terziroli Beretta‐Piccoli, B., Magro, B., Stättermayer, A., Cengiz, M., Clayton‐Chubb, D., Lammert, C., Bernsmeier, C., Gül, Ö., et al. (2022) · Hepatology · doi:10.1002/hep.32572 · Cited by 106
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni, G., Kirchner, T., Engel, B., Villamil, A. M., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., Lleo, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100605 · Cited by 37
Metadata
- Authors
- Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2022-01-07
- Volume
- 165
- Issue
- 4
- Pages
- 386-401
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W4200092905
- Cited by
- 502
- References
- 108
- FWCI
- 30.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New‐onset autoimmune phenomena post‐COVID‐19 vaccination. https://app.cochat.ai/papers/10.1111/imm.13443
- The paper
- Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H. (2022). New‐onset autoimmune phenomena post‐COVID‐19 vaccination. Immunology. https://doi.org/10.1111/imm.13443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.